On March 29, 2011, Kamila Novak of Antaea Medical Services, the clinical research organization that MAPS has hired to work on our Jordanian and Israeli MDMA/PTSD studies, met with the Jordanian Food and Drug Administration (JFDA) to discuss the status of our Jordanian study of MDMA-assisted psychotherapy for PTSD. The JFDA confirmed that the study had met the liability insurance requirements for subjects enrolled in the study and that the protocol was satisfactory, and that they will allow the study to proceed once a few final documents have been submitted, probably by the end of April.
